<DOC>
	<DOCNO>NCT00783211</DOCNO>
	<brief_summary>This randomize , double-blind , parallel-group , multicenter study use active control ( fexofenadine ) placebo control evaluate desloratadine 5 mg daily 15-day treatment period . The active treatment placebo allocate 2:2:1 ratio .</brief_summary>
	<brief_title>Efficacy Safety Desloratadine vs. Fexofenadine 180 mg. v . Placebo Treating Seasonal Allergic Rhinitis ( SAR ) ( Study P04053 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<mesh_term>Desloratadine</mesh_term>
	<mesh_term>Loratadine</mesh_term>
	<mesh_term>Fexofenadine</mesh_term>
	<mesh_term>Terfenadine</mesh_term>
	<criteria>demonstrate willingness participate study comply procedure , include adherence dose visit schedule sign write informed consent ( parent/guardian subject 18 year age also sign informed consent form ) ; 12 year age old , either sex race ; least 2year history ( selfreported history acceptable ) seasonal allergic rhinitis occur season ( ) current study ; skin test positive ( skin prick test wheal diameter least 3 mm large diluent control intradermal test wheal diameter least 7 mm large diluent control ) Screening , within 12 month prior Screening Visit , appropriate seasonal allergen , could include seasonal mold , prevalent geographical area study site study period ; female childbearing potential ( include woman less 1 year postmenopausal woman become sexually active study ) , use acceptable method birth control ( eg , hormonal contraceptive , medically prescribe IUD , condom combination spermicide ) surgically sterilize ( eg , hysterectomy tubal ligation ) ; female childbearing potential , negative urine pregnancy test Baseline ; free clinically significant disease ( SAR ) would interfere study evaluation ; understood able adhere dose visit schedule , agree record symptom severity score , medication time , concomitant medication , adverse event accurately consistently daily diary ; meet follow Screening Visit : total symptom score ( TSS ) 6 great ( include congestion ) , 2 symptom rat moderate ( 2 ) severe ( 3 ) symptom rat severe ( 4 ) 12 hour prior visit ; meet follow morning Baseline Visit : symptom severity score 7 AM instantaneous TSS 6 ( include congestion ) , 2 symptom rat moderate ( 2 ) severe ( 3 ) , symptom rat severe ( 4 ) . female , pregnant , intend become pregnant study , nursing ; observe designate washout period prohibit medication ; current evidence clinically significant hematopoietic , cardiovascular , hepatic , immunologic , renal , neurologic , psychiatric , autoimmune disease , disease preclude subject 's participation study ; particular attention give condition would interfere absorption , distribution , metabolism excretion study drug , subject 's ability complete diary card ; clinically significant deviation normal physical examination , investigator 's judgment , may interfere study evaluation affect subject safety ; situation condition , opinion investigator , may interfere optimal participation study ; participate clinical study ( y ) ; part investigational study staff family member staff personnel directly involve study ; asthma , exception mild intermittent asthma , ie , control use short acting , beta2agonist adrenoreceptor rescue medication ; current past history frequent ( 2 episode per year past 2 year ) , clinically significant sinusitis chronic purulent postnasal drip ; rhinitis medicamentosa ; history intranasal drug abuse ; history hypersensitivity study drug excipients , Claritin ; upper respiratory tract sinus infection require antibiotic therapy last dose within 14 day prior Screening , viral upper respiratory infection within 7 day prior Screening , persistent symptom time Screening Visit ; nasal structural abnormality , include nasal polyp easily visible physical examination mark septum deviation significantly interfere nasal airflow ; opinion investigator , dependent upon nasal , oral ocular decongestant , nasal topical antihistamine , nasal steroid ; immunotherapy ( desensitization therapy ) change dose study , remain dose throughout trial ; receive desensitization treatment within 24 hour prior visit ; previously randomize study study site ; ability provide inform consent compromise ; history noncompliance medication treatment protocol ; history difficulty swallow pill know upper gastrointestinal narrowing abnormal esophageal peristalsis ; nightshift worker standard asleep night / awake day cycle ; plan travel outside study area time participation study .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>